Outsourcing

Articles

The company is currently developing EVX-101 as an adjunctive treatment for MDD due to patients experiencing an inadequate response to first-line antidepressants such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors SNRIs.

Evecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone

There are many promising trials in the pipeline that may bring big news for major therapeutic areas.

Clinical Trials and their Impact on the Pharma Industry

The expanded operations will also support the start of proline/alanine/serine (PAS)-nomacopan clinical trials in geographic atrophy (GA).

Akari Therapeutics Establishes US Headquarters in Boston 

The initial collaboration between the two companies began in 2017 with an extension announced in 2021.

Regeneron Pharmaceuticals to Acquire Decibel Therapeutics 

The partnership is an extension of the collaboration from AbbVie and Scripps Research that was formed in 2019, according to the press release.

AbbVie Expands Collaboration with Calibr to Advance Clinical Assets

The document builds on key concepts outlined in ICH E8(R1) General Considerations for Clinical Studies.

Good Clinical Practice Draft Guidance Revealed for Clinical Studies

Hope is on the horizon as novel solutions and improvements aimed at benefitting the drug development process with the right framework are coming to the fore.

Moving Closer to Dynamic Drug Development 

clonoSEQ Assay is authorized by FDA for MRD assessment in lymphoid malignancies and is highly accurate, sensitive, and standardized compared to other technologies used for disease burden assessment. 

Adaptive Biotechnologies Announces Collaboration with Takeda for Minimal Residual Disease Measures

The efficacy data across multiple clinical endpoints and a favorable safety profile support the potential of AMB-05X as a best-in-class therapy for the treatment of TGCT regardless of surgical resectability.

AMB-05X Receives EMA PRIME Designation for Treatment of Tenosynovial Giant Cell Tumor

The merged company will operate under the name Ayala Pharmaceuticals and will target the development and commercialization of Ayala’s lead program, AL102, for the treatment of desmoid tumors. 

Clinical Trial Services